Tuesday, 30 September 2014


NYOH is the region's leading provider of community-based cancer care services.

The physicians and staff of New York Oncology Hematology (NYOH) are committed to reducing the incidence of cancer and blood diseases through earlier detection and intervention and offering their patients the most appropriate, evidence-based treatment options. With seven convenient locations, including five comprehensive cancer centers, the NYOH network provides world-class care to thousands of patients every year -- right here, close to home! Through our affiliation with US Oncology, one of the nation's largest cancer research networks, NYOH has played a pivotal role in the FDA approval process of 24 new anticancer drugs. Our special approach to cancer care allows us to have the best minds working together. To develop new treatments. To achieve more cures. To bring the breakthroughs home, as they happen!

New Patients






Dr. Weissman on Keytruda

New York Oncology Hematology’s Dr. Charles Weissman, an expert on melanoma, speaks with Newschannel 13 health reporter Benita Zahn about the groundbreaking FDA approval of anti-cancer drug Keytruda.

Jack Lewis, a patient of Dr. Weissman’s, who is currently participating in a clinical trial through New York Oncology Hematology for another melanoma treatment, shares his story and why he believes the clinical trial treatment is helping him live a longer life.

With the largest, most comprehensive clinical trial program in the region, New York Oncology Hematology and our patients have played a pivotal role in FDA approval of 38 anti-cancer drugs over the past 20 years.